Research ArticleProstate Cancer

Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer

See allHide authors and affiliations

Science Translational Medicine  06 Feb 2019:
Vol. 11, Issue 478, eaau5758
DOI: 10.1126/scitranslmed.aau5758

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Leave the fat out

Prostate cancer is one of the most common tumors in men. Although characterized by slow growth rate, preventing prostate cancer progression to an aggressive stage is a major challenge. Watt et al. focused on cancer metabolism and showed increased fatty acid uptake in human malignant prostate cancer tissue. The increased uptake was mediated by up-regulation of the fatty acid translocase CD36. Silencing CD36 in human prostate cancer cells reduced fatty acid uptake and cell proliferation. In prostate cancer mouse and human preclinical models, Cd36 ablation or inhibition reduced prostate cancer severity. The data suggest that CD36 might be targeted for treating prostate cancer.